PREEMPTIVE PHARMACOGENOMIC TESTING FOR PREVENTING ADVERSE DRUG REACTIONS (PREPARE): STATE OF ART AND PRELIMINARY RESULTS ON GENOTYPE ACTIONABILITY

In the last decade several studies have demonstrated that genetic variants in genes involved in drug metabolism and transport affect inter-individual variability in drug efficacy and safety. Since the 1st of January 2016an unique initiative has been launched in Europe with the financial support of Horizon 2020 program, Ubiquitous Pharmacogenomics (U-PGx), under the coordination of Leiden University Medical Center. The core of the project is the PREPARE randomized clinical trial that will be conducted in seven healthcare environments (The Netherlands, Spain, UK, Italy, Austria, Greece, Slovenia).. Primary aim of the study is to evaluate the effect of a pre-emptive pharmacogenomic approach on the prevention of toxic events and the improvement of patients quality of life.